Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 22 clinical trials
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

This phase III trial compares standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. Drugs used in chemotherapy, such as daunorubicin, cytarabine, and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by …

blast count
vision test
myeloid leukemia
etoposide
congenital heart block
  • 0 views
  • 2 annotations
  • 19 Feb, 2024
Comparison of Eligible TAVI-valves - Cohort B

The study performs head-to-head comparison of two TAVI-valves: Sapien and Myval.

tavi
  • 0 views
  • 19 Feb, 2024
Co-transplantation of MSC in the Setting of Allo-HSCT

Mesenchymal stem cells (MSCs) are known to exhibit immunomodulatory, anti-inflammatory, and pro-angiogenic properties, and therefore have the potential to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) .The study is aimed to identify and evaluate the potential benefits of MSCs infusion during allogeneic HSCT, with regard to the …

cell transplantation
ejection fraction
graft versus host disease
  • 0 views
  • 19 Feb, 2024
Treatment of BK Virus Infection With CTL Cells in Immunocompromised Transplant Patients

This is a pilot study using cytotoxic T lymphocytes (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Gamma-capture system will be effective in decreasing specific viral load in patients with BK virus viremia and BK virus-associated symptoms post-allogeneic hematopoietic stem cell transplantation (HSCT), renal transplantation, and chemotherapy.

  • 0 views
  • 19 Feb, 2024
Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to allogeneic stem cell transplantation (allo-HSCT) in patients with advanced myelodysplastic syndromes (MDS) .

cell transplantation
allogeneic hematopoietic stem cell transplant
myelodysplastic syndrome
myelodysplastic syndromes
raeb
  • 0 views
  • 19 Feb, 2024
Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day melphalan

  • 0 views
  • 19 Feb, 2024
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

The purpose of the CliniMACS TCR-Biotin System and CliniMACS CD19 is to improve the safety and efficacy of allogeneic HLA-partially matched related or unrelated donors HSCT when no matched donors are available, to treat malignant and nonmalignant disorders for which HSCT is the recommended best available therapy.

cardiovascular disease
direct bilirubin
renal function
alt/ast
ejection fraction
  • 0 views
  • 19 Feb, 2024
A Study Evaluating Gene Therapy With BB305 Lentiviral Vector in Sickle Cell Disease

The study will evaluate hematopoietic stem cell (HSC) transplantation (HSCT) with LentiGlobin BB305 Drug Product for SCD.

priapism
pediatric
gene therapy
karnofsky performance status
analgesia
  • 0 views
  • 19 Feb, 2024
Treatment of Refractory Diamond-Blackfan Anemia With Eltrombopag

Background Diamond-Blackfan anemia (DBA) is treated with steroids. But some people cannot take steroids, or steroids don t work. Other patients must get blood transfusions regularly which are time consuming and can have significant side effects. The drug eltrombopag can increase red blood cells. Researchers want to see if it …

electrocardiogram
blood transfusion
bone marrow biopsy
anemia
eltrombopag
  • 0 views
  • 19 Feb, 2024
Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD

Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of novel target agents is associated with worse outcome compared to the other forms. Response to steroids is observed only in about 10% of patients. The most promising approaches are JAK inhibition and fecal microbiota transplantation. In this pilot study …

ruxolitinib
acute graft-versus-host disease
graft versus host disease
  • 0 views
  • 19 Feb, 2024